14 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of pyridazinone derivatives bearing tetrahydroimidazo[1,2-a]pyrazine scaffold as potent inhibitors of transient receptor potential canonical 5 to ameliorate hypertension-induced renal injury in rats.
Nanjing University of Chinese Medicine
Discovery of N-alkyl-N-benzyl thiazoles as novel TRPC antagonists for the treatment of glioblastoma multiforme.
Yantai University
Discovery of potential novel TRPC5 inhibitors by virtual screening and bioassay.
Chinese Academy of Sciences
Biological Effects of Modifications of the Englerin A Glycolate.
National Cancer Institute
Discovery of pyrroledione analogs as potent transient receptor potential canonical channel 5 inhibitors.
China Pharmaceutical University
Synthesis of AC1903 analogs as potent transient receptor potential canonical channel 4/5 inhibitors and biological evaluation.
Chinese Academy of Sciences
Potential Treatment for Neuropsychiatry Disorders with TRPC5 Modulators.
Therachem Research Medilab (India)
Discovery of a Potent and Selective TRPC5 Inhibitor, Efficacious in a Focal Segmental Glomerulosclerosis Model.
Goldfinch Bio
Review of Transient Receptor Potential Canonical (TRPC5) Channel Modulators and Diseases.
University of Nebraska Medical Center
Design, synthesis and characterization of novel N-heterocyclic-1-benzyl-1H-benzo[d]imidazole-2-amines as selective TRPC5 inhibitors leading to the identification of the selective compound, AC1903.
University of Nebraska Medical Center
Discovery of Pyrrolidine Sulfonamides as Selective and Orally Bioavailable Antagonists of Transient Receptor Potential Vanilloid-4 (TRPV4).
TBA
